JMV1155

A novel inhibitor of glycine-extended progastrin-mediated growth of a human colon cancer in vivo

David A. Litvak, Mark Hellmich, Kazuhiro Iwase, B. Mark Evers, Jean Martinez, Muriel Amblard, Courtney Townsend

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: Glycine-extended progastrin (G-17-Gly), the immediate biosynthetic precursor to gastrin (G-17), stimulates growth of some gastrointestinal cancers in vitro. The purpose of this study was twofold: to evaluate the effects of G-17-Gly on a human colon cancer (DLD-1) in vivo and to determine whether the novel gastrin-receptor antagonist, JMV1155, inhibits G-17-Gly-mediated growth. Methods: DLD-1 cells (2 x 106) were injected subcutaneously (sc) at a single site in athymic nude mice. Mice were randomized to four groups (n = 6/group) to receive injections, sc, tid of either saline (control), G-17-Gly, JMV1155, or G-17-Gly + JMV1155 for 28 days. Tumors were measured biweekly until sacrifice at which time tumors were weighed and analyzed for DNA and protein content. Results: JMV1155 significantly inhibited G-17-GLY-stimulated growth of DLD-1 tumors by 14 days of treatment, producing a 56% decrease in tumor size by 28 days. JMV1155 also significantly decreased G-17-Gly-mediated increases in tumor weight (by 64%), DNA content (by 61%), and protein content (by 65%). Conclusions: We have demonstrated, for the first time, that the novel gastrin-receptor antagonist, JMV1155, blocks G-17-Gly-induced growth of a transplanted human colon cancer in vivo. Hormonally based therapy with JMV1155 potentially could be employed for some patients with colon carcinoma.

Original languageEnglish (US)
Pages (from-to)45-49
Number of pages5
JournalAnticancer Research
Volume19
Issue number1 A
StatePublished - 1999

Fingerprint

Colonic Neoplasms
Glycine
Growth
Cholecystokinin B Receptor
Nude Mice
Neoplasms
big gastrin
gastrin 17
Gastrointestinal Neoplasms
DNA
Tumor Burden
Colon
Proteins
Carcinoma
Injections
Therapeutics

Keywords

  • Colon cancer
  • Gastrin-receptor antagonist
  • Glycine-extended progastrin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

JMV1155 : A novel inhibitor of glycine-extended progastrin-mediated growth of a human colon cancer in vivo. / Litvak, David A.; Hellmich, Mark; Iwase, Kazuhiro; Evers, B. Mark; Martinez, Jean; Amblard, Muriel; Townsend, Courtney.

In: Anticancer Research, Vol. 19, No. 1 A, 1999, p. 45-49.

Research output: Contribution to journalArticle

Litvak, David A. ; Hellmich, Mark ; Iwase, Kazuhiro ; Evers, B. Mark ; Martinez, Jean ; Amblard, Muriel ; Townsend, Courtney. / JMV1155 : A novel inhibitor of glycine-extended progastrin-mediated growth of a human colon cancer in vivo. In: Anticancer Research. 1999 ; Vol. 19, No. 1 A. pp. 45-49.
@article{73bc2d22c81d4a49a0658385f94208d5,
title = "JMV1155: A novel inhibitor of glycine-extended progastrin-mediated growth of a human colon cancer in vivo",
abstract = "Background: Glycine-extended progastrin (G-17-Gly), the immediate biosynthetic precursor to gastrin (G-17), stimulates growth of some gastrointestinal cancers in vitro. The purpose of this study was twofold: to evaluate the effects of G-17-Gly on a human colon cancer (DLD-1) in vivo and to determine whether the novel gastrin-receptor antagonist, JMV1155, inhibits G-17-Gly-mediated growth. Methods: DLD-1 cells (2 x 106) were injected subcutaneously (sc) at a single site in athymic nude mice. Mice were randomized to four groups (n = 6/group) to receive injections, sc, tid of either saline (control), G-17-Gly, JMV1155, or G-17-Gly + JMV1155 for 28 days. Tumors were measured biweekly until sacrifice at which time tumors were weighed and analyzed for DNA and protein content. Results: JMV1155 significantly inhibited G-17-GLY-stimulated growth of DLD-1 tumors by 14 days of treatment, producing a 56{\%} decrease in tumor size by 28 days. JMV1155 also significantly decreased G-17-Gly-mediated increases in tumor weight (by 64{\%}), DNA content (by 61{\%}), and protein content (by 65{\%}). Conclusions: We have demonstrated, for the first time, that the novel gastrin-receptor antagonist, JMV1155, blocks G-17-Gly-induced growth of a transplanted human colon cancer in vivo. Hormonally based therapy with JMV1155 potentially could be employed for some patients with colon carcinoma.",
keywords = "Colon cancer, Gastrin-receptor antagonist, Glycine-extended progastrin",
author = "Litvak, {David A.} and Mark Hellmich and Kazuhiro Iwase and Evers, {B. Mark} and Jean Martinez and Muriel Amblard and Courtney Townsend",
year = "1999",
language = "English (US)",
volume = "19",
pages = "45--49",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 A",

}

TY - JOUR

T1 - JMV1155

T2 - A novel inhibitor of glycine-extended progastrin-mediated growth of a human colon cancer in vivo

AU - Litvak, David A.

AU - Hellmich, Mark

AU - Iwase, Kazuhiro

AU - Evers, B. Mark

AU - Martinez, Jean

AU - Amblard, Muriel

AU - Townsend, Courtney

PY - 1999

Y1 - 1999

N2 - Background: Glycine-extended progastrin (G-17-Gly), the immediate biosynthetic precursor to gastrin (G-17), stimulates growth of some gastrointestinal cancers in vitro. The purpose of this study was twofold: to evaluate the effects of G-17-Gly on a human colon cancer (DLD-1) in vivo and to determine whether the novel gastrin-receptor antagonist, JMV1155, inhibits G-17-Gly-mediated growth. Methods: DLD-1 cells (2 x 106) were injected subcutaneously (sc) at a single site in athymic nude mice. Mice were randomized to four groups (n = 6/group) to receive injections, sc, tid of either saline (control), G-17-Gly, JMV1155, or G-17-Gly + JMV1155 for 28 days. Tumors were measured biweekly until sacrifice at which time tumors were weighed and analyzed for DNA and protein content. Results: JMV1155 significantly inhibited G-17-GLY-stimulated growth of DLD-1 tumors by 14 days of treatment, producing a 56% decrease in tumor size by 28 days. JMV1155 also significantly decreased G-17-Gly-mediated increases in tumor weight (by 64%), DNA content (by 61%), and protein content (by 65%). Conclusions: We have demonstrated, for the first time, that the novel gastrin-receptor antagonist, JMV1155, blocks G-17-Gly-induced growth of a transplanted human colon cancer in vivo. Hormonally based therapy with JMV1155 potentially could be employed for some patients with colon carcinoma.

AB - Background: Glycine-extended progastrin (G-17-Gly), the immediate biosynthetic precursor to gastrin (G-17), stimulates growth of some gastrointestinal cancers in vitro. The purpose of this study was twofold: to evaluate the effects of G-17-Gly on a human colon cancer (DLD-1) in vivo and to determine whether the novel gastrin-receptor antagonist, JMV1155, inhibits G-17-Gly-mediated growth. Methods: DLD-1 cells (2 x 106) were injected subcutaneously (sc) at a single site in athymic nude mice. Mice were randomized to four groups (n = 6/group) to receive injections, sc, tid of either saline (control), G-17-Gly, JMV1155, or G-17-Gly + JMV1155 for 28 days. Tumors were measured biweekly until sacrifice at which time tumors were weighed and analyzed for DNA and protein content. Results: JMV1155 significantly inhibited G-17-GLY-stimulated growth of DLD-1 tumors by 14 days of treatment, producing a 56% decrease in tumor size by 28 days. JMV1155 also significantly decreased G-17-Gly-mediated increases in tumor weight (by 64%), DNA content (by 61%), and protein content (by 65%). Conclusions: We have demonstrated, for the first time, that the novel gastrin-receptor antagonist, JMV1155, blocks G-17-Gly-induced growth of a transplanted human colon cancer in vivo. Hormonally based therapy with JMV1155 potentially could be employed for some patients with colon carcinoma.

KW - Colon cancer

KW - Gastrin-receptor antagonist

KW - Glycine-extended progastrin

UR - http://www.scopus.com/inward/record.url?scp=0032921643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032921643&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 45

EP - 49

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 A

ER -